SPDR S&P Kensho New Economies Composite ETF (ARCA: KOMP)

에 대한 최신 뉴스 SPDR S&P Kensho New Economies Composite ETF (ARCA:KOMP)

Technology

Industrials

Healthcare

Financial Services

Consumer Cyclical

Communication Services

Basic Materials

Utilities

Energy

Consumer Defensive

Other

Under normal market conditions, the fund generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index is designed to capture companies whose products and services are driving innovation and transforming the global economy through the use of existing and emerging technologies, and rapid developments in robotics, automation, artificial intelligence, connectedness and processing power. The fund is non-diversified.

Oceaneering International Inc

Teledyne Technologies Inc

Parsons Corporation Com

Bruker Corp.

Coinbase Global, Inc.

Kratos Defense & Security Solutions, Inc.

Lockheed Martin Corp

Leidos Holdings, Inc.

Paysafe Ltd

Aerovironment Inc

Elbit Systems

Lexinfintech Holdings Ltd

Osi Systems Inc

Irhythm Technologies, Inc.

Ehang Holdings Ltd

Intuitive Machines Inc A

Masimo Corp

Elbit Systems Ltd

Northrop Grumman Corp.

Mercadolibre Inc

Rocket Lab Usa Inc

SPDR S&P Kensho New Economies Composite ETF

Harvard University will urge a federal judge Monday to block President Donald Trump&#8216;s proclamation barring foreign nationals from studying at the institution. According to Reuters, U.S. District Judge Allison Burroughs will consider extending a temporary restraining order during a Boston hearing as the university challenges restrictions affecting 6,800 international students.
What Happened: Trump signed a proclamation June 5 suspending entry of foreign nationals to study at Harvard for six months, citing national security concerns. The directive claimed Harvard has &#8220;extensive entanglements with foreign adversaries&#8221; and &#8220;concerning foreign ties and radicalism.&#8221; International students comprise<a href="https://www.benzinga.com/25/05/45671848/kevin-oleary-says-international-students-are-extraordinary-individuals-he-adds-they-dont-hate-america-and-i-want-to-invest-in-them"> 27% of Harvard&#8217;s enrollment</a>, with China and India as top origin countries.
Judge Burroughs issued a temporary restraining order June 6 preventing implementation while Harvard&#8217;s lawsuit proceeds. The university filed two separate legal challenges seeking to unfreeze $2.5 billion in federal funding and prevent international student restrictions. 
The administration has <a href="https://www.benzinga.com/news/politics/25/06/45879240/secretatry-of-state-marco-rubio-pushes-sanctions-probe-into-harvard-over-ties-to-blacklisted-chinese-entity-report">frozen $3 billion in Harvard grants</a> and proposed ending the university&#8217;s tax-exempt status. Homeland Security Secretary Kristi Noem revoked Harvard&#8217;s Student and Exchange Visitor Program certification May 22, but Burroughs temporarily blocked that action.
Secretary of State Marco Rubio is pursuing a federal sanctions investigation into Harvard over alleged violations involving a blacklisted Chinese entity. Trump&#8217;s proclamation instructs Rubio to consider revoking current students&#8217; visas and allows extensions beyond six months.
Harvard argues the administration is retaliating for the university&#8217;s refusal to accept federal demands controlling governance, curriculum, and faculty ideology, violating First Amendment protections. The Justice Department contends Trump&#8217;s proclamation should be considered separately from previous actions. See Also: <a href="https://www.benzinga.com/markets/tech/25/06/45945298/tesla-model-3-on-fsd-mode-struck-by-train-after-getting-trapped-on-railroad-tracks-report">Tesla Model 3 On FSD Mode Struck By Train After Getting Trapped On Railroad Tracks: Report</a>
Why It Matters: The administration has revoked over 1,500 student visas across 222 schools nationwide, creating institutional uncertainty. International students contribute $44 billion annually to the U.S. economy and support 378,000 jobs. Japan&#8217;s Education Minister <a href="https://www.benzinga.com/news/legal/25/06/45786819/trump-suspends-entry-of-foreign-students-to-harvard-for-six-months-citing-national-security-university-calls-move-illegal-retaliatory-step">announced universities would welcome displaced Harvard students</a>, including 110 Japanese nationals currently enrolled. The legal outcome could establish precedent for federal authority over university international programs and First Amendment protections in higher education.
Image via Shutterstock Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/fda/25/06/45945282/sarepta-therapeutics-stock-plummets-over-40-on-second-fatal-case-linked-to-its-gene-therapy">Sarepta Therapeutics Stock Plummets Over 40% On Second Fatal Case Linked To Its Gene Therapy</a> Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.</li>
</ul>

Politics

Harvard To Ask Judge To Extend Block On Trump's Foreign Student Ban,  Citing Retaliation And Free Speech Violations

WIIM

Smurfit WestRock shares are trading higher after Jefferies upgraded the stock from Hold to Buy and raised its price target from $44 to $55.

NRx Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) ("NRx Pharmaceuticals", "NRx" or the "Company"), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc., ("HOPE," or the "Company"), a multi-site clinical care delivery organization and wholly-owned subsidiary of NRx, today announced a strategic investor relations partnership with&nbsp;astr partners, a boutique investor relations and capital advisory firm focused on the life sciences sector.

News

NRXP

NRx Pharmaceuticals And HOPE Therapeutics Announce Strategic Investor Relations Partnership With Life Sciences Advisory Firm Astr Partners

SUNation Energy, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/SUNE#NASDAQ">SUNE</a>) ("the Company"), a leading provider of sustainable solar energy and backup power solutions for households, businesses, and municipalities, today announced that, by a decision dated June 10, 2025, the Nasdaq Hearings Panel (the "Panel") made a finding that the Company is not in violation of Nasdaq Listing Rules 5100 and 5550(a)(2), the "Public Interest Concern" and "Bid Price Rule", respectively, which were the bases of the non-compliance and delisting notices previously provided to and disclosed by the Company.
Accordingly, the Company is deemed to be in full compliance with the applicable Nasdaq Listing Rules, and the Panel granted the Company's request for continued listing on The Nasdaq Stock Market LLC ("Nasdaq") and is closing this matter.

SUNE

SUNation Energy Secures Nasdaq Compliance After Panel Finds No Rule Violations

CELH

Celsius Holdings shares are trading higher after TD Cowen upgraded the stock from Hold to Buy and raised its price target from $37 to $55.

UBS analyst Bryan Adams initiates coverage on Conagra Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAG#NYSE">CAG</a>) with a Neutral rating and announces Price Target of $22.

Price Target

Initiation

Analyst Ratings

UBS Initiates Coverage On Conagra Brands with Neutral Rating, Announces Price Target of $22

JMP Securities analyst Nicholas Jones downgrades Angi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGI#NASDAQ">ANGI</a>) from Market Outperform to Market Perform.

Downgrades

ANGI

JMP Securities Downgrades Angi to Market Perform

INCY

Incyte shares are trading higher after the company announced a collaboration with QIAGEN to develop a novel diagnostic panel to support its portfolio of investigational therapies for patients with myeloproliferative neoplasms. Also, the company announced first clinical data from two studies evaluating the safety, tolerability and efficacy of INCA033989.

The Phase 2 Istaroxime study was successful in multiple endpoints showing promise for how it may be utilized if approved in its targeted indications&nbsp;&nbsp;&nbsp;
Primary endpoint of the study was met of increasing systolic blood pressure and demonstration of other benefits including no increase in heart rate and preserved renal function
Partnership discussions with multiple potential partners that may fund the remainder of clinical development thus eliminating the Company's cash burn with the cardiovascular pipeline
Phase 2 SEISMiC C interim data results targeted for July
Final stages of protocol design for Phase 3 in acute heart failure indication for China nearly complete for regional license partner and will be fully funded by the licensee
WARRINGTON, Pa., June 16, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a diversified company focused on revenue generation in multiple growing industries, announced that the istaroxime early cardiogenic shock Phase 2 study called SEISMiC B is published in the Journal of Heart and Lung Transplantation and is available on the journal website. The publication is entitled "Safety and Efficacy Intravenous Istaroxime up to 60 hours for Patients with Pre-Cardiogenic Shock.1" Patients with this condition have poor cardiac function, low blood pressure and need rapid treatment.
The article notes in the SEISMiC B study that istaroxime significantly increased blood pressure over the first six hours of treatment and persisted for 60 hours. Patients also had significantly improved cardiac output, decreased pulmonary capillary wedge pressure (a measure of fluid back up), no increase in heart rate, no increase in clinically significant arrythmias and preserved renal function, a very unique profile of potential beneficial effects for this patient population.
An accompanying editorial highlighted the encouraging results and described istaroxime as, "a potential new approach to heart failure-cardiogenic shock in which the next frontier is not just survival, but earlier and smarter stabilization.2"
Istaroxime has completed four positive Phase 2 studies, including two in early cardiogenic shock (called SCAI Stage B). Market research conducted by the Company with U.S. based clinical cardiologists reveals a high desire for cardiogenic shock drug treatment innovation.

Biotech

General

WINT

Windtree Therapeutics' Istaroxime Achieves Success In Phase 2 SEISMiC B Study, Meeting Primary Endpoint And Showing Cardiogenic Shock Benefits Without Increasing Heart Rate Or Renal Risk

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2025/06/13/final-trades-alphabet-unitedhealth-schlumberger-and-the-iye.html">Halftime Report Final Trades</a>,&#8221; Rob Sechan, CEO of NewEdge Wealth, recommended buying Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>). The stock has been the best performer in the Magnificent Seven over the past month and <a href="https://www.benzinga.com/markets/tech/25/06/45899809/ericsson-google-cloud-launch-new-tool-to-help-telecoms-build-faster-smarter-networks">is the cheapest as well.</a>
As per recent news, Ericsson announced on June 12 the launch of Ericsson On-Demand, a new solution delivering core network services as a true software-as-a-service (SaaS) platform to communications service providers (CSPs). The platform is designed with Alphabet Google Cloud, leveraging AI infrastructure and Google Kubernetes Engine (GKE), and is managed end-to-end by Ericsson.
Shannon Saccocia, CFA, is the chief investment officer of NB Private Wealth, named iShares U.S. Energy ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYE#NYSE">IYE</a>) as her final trade.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage her</a>e
Sarat Sethi, DCLA managing partner and portfolio manager, picked Schlumberger Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) as his final trade.
On the earnings front, Schlumberger reported worse-than-expected first-quarter 2025 results on April 25. Revenue declined 3% year over year to $8.49 billion, missing estimates of $8.59 billion. Adjusted EPS slid 4% to 72 cents, missing the consensus of 74 cents.
Stephen Weiss, chief investment officer and managing partner of Short Hills Capital Partners, said UnitedHealth Group Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) is a good trade from here.
As per recent news, UnitedHealth Group re-elected all current directors on June 4. The board authorized the payment of a cash dividend of $2.21 per share, up from the prior dividend of $2.10, to be paid on June 24 to common stock shareholders of record as of the close of business on June 16.
Price Action:
<ul class="wp-block-list">
<li>Alphabet shares fell 0.6% to close at $174.67 on Friday.</li>
<li>iShares U.S. Energy ETF rose 1.8% during the session.</li>
<li>UnitedHealth shares fell 1.6% to settle at $313.53 on Friday.</li>
<li>SLB shares gained 1.9% to settle at $36.30 during the session.</li>
</ul>
Check This Out:<a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45924005/top-2-energy-stocks-that-may-fall-off-a-cliff-in-june"> </a>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45924005/top-2-energy-stocks-that-may-fall-off-a-cliff-in-june">Top 2 Energy Stocks That May Fall Off A Cliff in June</a></li>
</ul>
Photo: Shutterstock

Markets

Media

Trading Ideas

GOOG

GOOGL

iShares Dow Jones US Energy Sector Index Fund

UnitedHealth Group, Schlumberger, Alphabet And More On CNBC's 'Final Trades'

Natural Gas Services Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NGS#NYSE">NGS</a>), a leading provider of natural gas compression equipment, technology, and services to the energy industry, today announced that Stephen C. Taylor has transitioned from Chairman of the Board to the role of Chairman Emeritus, effective immediately. Concurrently, the Company's Board of Directors has appointed Donald J. Tringali as Chairman. Mr. Taylor continues his role as a director on the Company's Board.

Management

Natural Gas Services Appoints Donald Tringali As Chairman; Says Stephen Taylor Transitioned From Chairman Of Board To Chairman Emeritus, Effective Immediately

Refinements to probe configuration and proprietary algorithms are expected to drive substantial improvements in MRI-PDFF correlation
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fendrainc.com%2F&amp;esheet=54274068&amp;newsitemid=20250616575045&amp;lan=en-US&amp;anchor=ENDRA+Life+Sciences+Inc.&amp;index=1&amp;md5=d3b8793be6994cca89b77baa3171adab">ENDRA Life Sciences Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>), a pioneer in imaging technologies for the early detection and monitoring of metabolic liver disease, today announced that its ongoing multisite pilot study has helped to identify several product enhancements to further improve the performance of its TAEUS&#xAE; Liver system against the gold standard, MRI. These findings are expected to drive substantial improvements to the device's probe design and proprietary algorithms, measurably improving diagnostic accuracy and repeatability. These enhancements are currently being implemented and are expected to strengthen the outcomes of the Company's planned U.S. Food and Drug Administration ("FDA") De Novo pivotal study.
Consistent with its revamped go-to-market strategy, ENDRA is conducting a multisite clinical initiative designed to bolster the diagnostic performance of TAEUS Liver prior to initiation of the FDA pivotal study. In collaboration with several leading imaging centers, the Company has collected liver fat measurement data from more than 100 subjects that compare TAEUS scans against MRI-PDFF.

NDRA

ENDRA Life Sciences Announces That Its Ongoing Multisite Pilot Study Has Helped To Identify Several Product Enhancements To Further Improve The Performance Of Its TAEUS Liver System Against The Gold Standard, MRI

NITO

N2OFF Increases Investment In Melz Project To Explore Integrating Additional 40-60 MW Battery Storage

<ul>
<li>The test, run on Abbott's portable i-STAT&#xAE; Alinity&#xAE; instrument, uses whole blood to help evaluate patients with a suspected mild traumatic brain injury (mTBI), otherwise known as concussion</li>
<li>The test produces lab-quality results in 15 minutes</li>
<li>Clinicians can get a result at the patient's bedside, making the test accessible at urgent care clinics and healthcare settings outside of the hospital emergency room</li>
<li>The test can be used to help evaluate patients up to 24 hours after injury</li>
</ul>
MISSISSAUGA, ON, June 16, 2025 /CNW/ -- Abbott (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) announced today that Health Canada has approved the company's&nbsp;i-STAT TBI test cartridge for use with whole blood, helping clinicians to assess suspected concussion at the patient's bedside and obtain lab-quality results in 15 minutes. Previously, the tests used to help assess mild traumatic brain injury (mTBI) were only authorized for use with plasma or serum, requiring samples to be sent to a lab for processing.

Health Canada Approves Abbott's i-STAT TBI Test Cartridge For Use With Whole Blood, To Assess Suspected Concussion At Patient's Bedside And Obtain Lab-Quality Results In 15 Minutes

Achievement demonstrates manufacturer's drive for excellence in drone production&nbsp;
Cheseaux-sur-Lausanne, Switzerland, June 16, 2025 (GLOBE NEWSWIRE) -- AgEagle Aerial Systems Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAVS#NYSE">UAVS</a>), a leading provider of advanced drone and aerial imaging solutions, is proud to announce their Switzerland facility has been recommended to receive ISO 9001 certification by third-party auditors following an intensive review of the facilities Quality Management System. This prestigious certification reflects AgEagle's commitment to excellence, safety, and innovation.
The ISO 9001 standard is widely recognized across all industries and sets rigorous requirements for quality management, customer satisfaction, risk mitigation, safety, and continuous improvement. Earning this certification for the Switzerland facility—home to key research, development, and manufacturing of AgEagle's cutting-edge drone technologies—demonstrates:
<ul>
<li>Unmatched Quality Assurance: The facility meets the highest industry standards for producing reliable drone systems, such as the eBee TAC Public Safety drone and the eBee VISION drone, ensuring precision and performance for worldwide customers. &nbsp;</li>
<li>Operational Excellence: The process highlights AgEagle's dedication to streamlining production and maintaining safety, supporting sustainable farming innovations and bringing new technologies to market &nbsp;</li>
<li>Enhanced Global Trust: Certification strengthens AgEagle's credibility with international clients, including governments and procurement agencies, aligning with the company's growth into Intelligence, Surveillance and Reconnaissance (ISR) marketplaces and public safety operators. &nbsp;</li>
</ul>

UAVS

AgEagle Aerial Systems' Switzerland Facility Recommended To Receive ISO 9001 Certification By Third-Party Auditors Following An Intensive Review Of The Facilities Quality Management System

XAIR

Beyond Air Submits A Premarket Approval Supplement Application To The FDA For LungFit PH II

<h3>Gainers</h3>
<ul>
<li>SharpLink Gaming (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBET#NASDAQ">SBET</a>) shares rose 20.9% to $11.14 during Monday's pre-market session. The company's market cap stands at $7.7 million. </li>
<li>Twin Hospitality Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWNP#NASDAQ">TWNP</a>) shares rose 20.07% to $6.04. The company's market cap stands at $346.1 million. </li>
<li>Yunji (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YJ#NASDAQ">YJ</a>) shares rose 14.18% to $1.9. The company's market cap stands at $37.3 million. </li>
<li>ZHONGCHAO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZCMD#NASDAQ">ZCMD</a>) shares moved upwards by 13.0% to $1.3. The market value of their outstanding shares is at $32.8 million. </li>
<li>Naas Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAAS#NASDAQ">NAAS</a>) stock increased by 12.14% to $1.2. The market value of their outstanding shares is at $16.5 million. </li>
<li>SRM Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRM#NASDAQ">SRM</a>) shares increased by 9.65% to $1.59. The company's market cap stands at $27.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Fitell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTEL#NASDAQ">FTEL</a>) stock declined by 16.8% to $0.38 during Monday's pre-market session. The company's market cap stands at $7.5 million. </li>
<li>Jiuzi Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JZXN#NASDAQ">JZXN</a>) shares declined by 10.33% to $1.39. The company's market cap stands at $15.3 million. </li>
<li>Boqii Holding (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BQ#AMEX">BQ</a>) shares decreased by 7.55% to $1.96. The market value of their outstanding shares is at $6.0 million. </li>
<li>Wag Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PET#NASDAQ">PET</a>) stock declined by 7.26% to $0.11. The company's market cap stands at $5.5 million. </li>
<li>Genius Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GNS#AMEX">GNS</a>) shares declined by 6.36% to $0.36. The market value of their outstanding shares is at $25.7 million. </li>
<li>LiveWire Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LVWR#NYSE">LVWR</a>) shares decreased by 5.47% to $5.36. The company's market cap stands at $1.0 billion. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

FTEL

JZXN

LVWR

NAAS

SBET

TWNP

ZCMD

12 Consumer Discretionary Stocks Moving In Monday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) shares rose 37.5% to $9.21 during Monday's pre-market session. The company's market cap stands at $576.7 million. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares increased by 37.43% to $0.03. The company's market cap stands at $11.3 million. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) shares increased by 20.58% to $0.39. The company's market cap stands at $11.8 million. </li>
<li>Applied DNA Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) shares increased by 17.21% to $5.48. The market value of their outstanding shares is at $2.8 million. </li>
<li>HeartBeam (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAT#NASDAQ">BEAT</a>) shares rose 15.89% to $1.75. The market value of their outstanding shares is at $59.1 million. </li>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) shares rose 15.49% to $0.13. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) stock decreased by 39.8% to $21.79 during Monday's pre-market session. The market value of their outstanding shares is at $2.1 billion. </li>
<li>Jupiter Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JUNS#NASDAQ">JUNS</a>) stock decreased by 11.51% to $1.0. The market value of their outstanding shares is at $33.1 million. </li>
<li>Catheter Precision (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#AMEX">VTAK</a>) shares fell 11.21% to $0.32. The company's market cap stands at $4.0 million. </li>
<li>Co-Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CODX#NASDAQ">CODX</a>) stock declined by 9.36% to $0.25. The company's market cap stands at $8.4 million. </li>
<li>Imunon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) stock declined by 7.69% to $1.32. The market value of their outstanding shares is at $23.1 million. </li>
<li>Biofrontera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRI#NASDAQ">BFRI</a>) stock fell 7.39% to $0.61. The company's market cap stands at $5.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APDN

BEAT

BFRI

CODX

HCTI

IMNN

JUNS

NCNA

ONMD

SAGE

SRPT

VTAK

12 Health Care Stocks Moving In Monday's Pre-Market Session

Crown Holdings To Promote Djalma Novaes Jr., To EVP And COO, Effective July 1, 2025

PHAT

Phathom Pharmaceuticals Announces FDA Updated The Orange Book To Reflect The 10-Year Period Of Non-Patent New Chemical Entity Exclusivity For VOQUEZNA

Comments

SPDR S&P Kensho New Economies Composite ETF

뉴스

에 대한 최신 뉴스 SPDR S&P Kensho New Economies Composite ETF (ARCA:KOMP)

뉴스

파트너 / 기고자

벤징가 글로벌